By Diagnostics World Staff
December 4, 2017 | Vanderbilt University Medical Center announced integration of FDNA’s Face2Gene suite of applications into the Vanderbilt Center for Undiagnosed Diseases workflow to evaluate difficult-to-diagnose patients in their role as part of the National Institutes of Health (NIH) Undiagnosed Disease Network (UDN).
Participating institutions in the UDN use the most advanced approaches in genomics and research to search for answers for patients who have been unable to find a diagnosis. The UDN is made up of seven top-ranked institutions in the United States. Vanderbilt University Medical Center approached FDNA to use Face2Gene for UDN cases.
“FDNA’s mission aligns perfectly with Vanderbilt and the UDN,” said Dekel Gelbman, CEO of FDNA in a press release. “We are all working to find answers for patients who have waited far too long, and with this collaboration, we believe we are one step closer.”
Face2Gene is a platform that uses next-generation phenotyping (NGP) technologies to analyze a patient’s facial and clinical features to highlight syndromes and genetics that may have otherwise been missed during patient evaluations. The company reports that the platform is used by more than 70% of clinical geneticists globally.